ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Actinium Pharmaceuticals, Inc. ?
1
With a growth in Net Sales of INF%, the company declared Outstanding results in Jun 26
- The company has declared positive results for the last 5 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD -22.66 MM
- ROCE(HY) Highest at 45.86%
- RAW MATERIAL COST(Y) Fallen by -9,877% (YoY)
2
With ROE of -251.01%, it has a does not qualify valuation with a 2.33 Price to Book Value
- Over the past year, while the stock has generated a return of -26.06%, its profits have risen by 15.4%
3
High Institutional Holdings at 29.68%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Actinium Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Actinium Pharmaceuticals, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Actinium Pharmaceuticals, Inc.
-27.16%
5.20
69.29%
S&P 500
15.76%
1.17
13.09%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
1.74%
EBIT Growth (5y)
-28.53%
EBIT to Interest (avg)
-37.29
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-2.52
Sales to Capital Employed (avg)
0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
29.59%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.33
EV to EBIT
0.55
EV to EBITDA
0.57
EV to Capital Employed
0.53
EV to Sales
-20.65
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
95.75%
ROE (Latest)
-251.01%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend31What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -22.66 MM
ROCE(HY)
Highest at 45.86%
RAW MATERIAL COST(Y)
Fallen by -9,877% (YoY
NET SALES(9M)
Higher at USD 35 MM
OPERATING PROFIT(Q)
Highest at USD 28 MM
PRE-TAX PROFIT(Q)
Highest at USD 27.9 MM
NET PROFIT(Q)
Highest at USD 27.9 MM
EPS(Q)
Highest at USD 0.89
-2What is not working for the Company
CASH AND EQV(HY)
Lowest at USD 78.6 MM
DEBT-EQUITY RATIO
(HY)
Highest at -115.94 %
Here's what is working for Actinium Pharmaceuticals, Inc.
Net Sales
At USD 35 MM has Grown at inf%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Pre-Tax Profit
At USD 27.9 MM has Grown at 575.5%
over average net sales of the previous four periods of USD -5.87 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 27.9 MM has Grown at 575.5%
over average net sales of the previous four periods of USD -5.87 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Operating Cash Flow
Highest at USD -22.66 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Operating Profit
Highest at USD 28 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD 27.9 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 27.9 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 0.89
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Net Sales
Higher at USD 35 MM
than preceding 12 month period ended Jun 2026MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Raw Material Cost
Fallen by -9,877% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Actinium Pharmaceuticals, Inc.
Cash and Eqv
Lowest at USD 78.6 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at -115.94 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Footer loading
